Page 8 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Contents
Chapter 1 General introduction 9
DPYD genotyping: proof of principle and implementation in clinical practice
Chapter 2
Chapter 3
Chapter 4
Chapter 5
Chapter 6
Chapter 7
Chapter 8
Chapter 9
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine- 23 induced severe toxicity: ready for prime time
Eur J Cancer. 2016;54:40-8
Translating DPYD genotype into DPD phenotype: using the DPYD gene 39 activity score
Pharmacogenomics. 2015;16(11):1277-86
Dutch Pharmacogenetics Working Group (DPWG) guideline for the 57 gene-drug interaction of DPYD and fluoropyrimidines
Submitted (under review)
DPYD genotype-guided dose individualisation of fluoropyrimidine 149 therapy in patients with cancer: a prospective safety analysis
Lancet Oncol. 2018;19(11):1459-1467
A cost analysis of upfront DPYD genotype-guided dose individualisation 179 in fluoropyrimidine-based anticancer therapy
Eur J Cancer. 2018;107:60-7
Standard fluoropyrimidine dosages in chemoradiation therapy result in 193 an increased risk of severe toxicity in DPYD variant allele carriers
Eur J Cancer. 2018;104:210-8
Evaluation of clinical implementation of prospective DPYD genotyping in 215 5-fluorouracil- or capecitabine-treated patients
Pharmacogenomics. 2016;17(7):721-9
Confirmation practice in pharmacogenetic testing; how good is good 231 enough?
Clin Chim Acta. 2018;490:77-80